Patents by Inventor Paul Parren

Paul Parren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20180194849
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 12, 2018
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20180194845
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 12, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20180179286
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: June 28, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180179270
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: June 28, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180179271
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: June 28, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Antibody variants having modifications in the constant region
    Patent number: 10000570
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: June 19, 2018
    Assignee: Genmab A/S
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
  • HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
    Publication number: 20180134783
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 26, 2016
    Publication date: May 17, 2018
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180127491
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 10, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180127492
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 10, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Antibodies against human CD38
    Patent number: 9944711
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 17, 2018
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20180044431
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 19, 2017
    Publication date: February 15, 2018
    Inventors: Sandra VERPLOEGEN, David P.E. SATIJN, Rene M.A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, Tom VINK, Willam Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE
    Publication number: 20180022816
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: June 20, 2017
    Publication date: January 25, 2018
    Applicant: GENMAB A/S
    Inventors: Bart DE GOEIJ, Edward N. VAN DEN BRINK, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, D.M.Sc., David SATIJN, Jan VAN DE WINKEL, Paul PARREN
  • Monoclonal antibodies against HER2
    Patent number: 9862769
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 9, 2018
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
    Publication number: 20170369594
    Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 28, 2017
    Inventors: Joost J. NEIJSSEN, Joyce I. MEESTERS, Bart DE GOEIJ, Aran Frank LABRIJN, Paul PARREN, Janine SCHUURMAN
  • BISPECIFIC ANTIBODIES AGAINST HER2
    Publication number: 20170369590
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 28, 2017
    Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN
  • POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
    Publication number: 20170362319
    Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.
    Type: Application
    Filed: January 24, 2017
    Publication date: December 21, 2017
    Inventors: Catharina Emanuele GERARDA HAVENITH, Tom VINK, Patrick VAN BERKEL, Paul PARREN
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20170355767
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Application
    Filed: January 8, 2016
    Publication date: December 14, 2017
    Inventors: Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
    Publication number: 20170334984
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 26, 2016
    Publication date: November 23, 2017
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
  • RODENT BISPECIFIC HETERODIMERIC PROTEINS
    Publication number: 20170327597
    Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 16, 2017
    Applicant: GENMAB A/S
    Inventors: Aran F. LABRIJN, Joyce I. MEESTERS, Janine SCHUURMAN, Paul PARREN, Anthony ARMSTRONG, Matthew BUNCE, Mark CHIU, Thomas NESSPOR, Adam ZWOLAK
  • MONOCLONAL ANTIBODIES AGAINST C-MET
    Publication number: 20170320962
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: April 19, 2017
    Publication date: November 9, 2017
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL